AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS)

LC Coates; TK Kvien; P Nash; L Gossec; V Strand; L Pricop; L Rasouliyan; K Ding; S Jugl; C Gaillez; on behalf of the FUTURE 2 study group

doi:10.1136/annrheumdis-2017-eular.1482

Citation Tools

Abstracts Accepted for Publication

Psoriatic arthritis

AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS)

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Coates L, Kvien T, Nash P, et al

AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS)

Annals of the Rheumatic Diseases 2017;76:1326.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password